Ganeden Biotech expands footprint of probiotic ingredient

Ganeden Biotech's probiotic ingredient GanedenBC³⁰ has received numerous international regulatory approvals and is now being shipped to six of the seven continents.

'Achieving a global footprint for GanedenBC³⁰ has been an ongoing goal for Ganeden Biotech that could only be achieved by a significant investment in international regulatory compliance and patent prosecution, working with international distributors and continuing to publish studies in peer reviewed journals that support claims for safety and efficacy,' said Mike Bush, Senior VP at Mayfield Heights, Ohio, US-based Ganeden Biotech.

Ganeden Biotech has received regulatory approvals for GanedenBC³⁰ in over 60 countries throughout North America, Asia, Europe, South America, Africa, and Oceania, which has resulted in six international product launches in the first quarter of 2014.

By the end of the year Ganeden expects to receive approvals in six more countries, with many more to come in 2015.

The global market for probiotic ingredients, supplements and foods reached nearly US$27.1bn in 2013 and is expected to climb at a compound annual growth rate of 6.2% over the next four years to $36.7bn in 2018, according to US market research company, BCC Research.